News


Sygnature is delighted to be hosting Kinase 2016 on 16th and 17th May 2016 in Nottingham

Organised by the SCI’s Fine Chemicals Group and the RSC’s Biological and Medicinal Chemistry sector in partnership with Sygnature Discovery,  Kinase 2016: Next Generation Inhibitors will focus on several pertinent themes including new approaches and technologies to modulate and measure kinase function in addition to diverse medicinal chemistry case studies. The 2 day event includes an […]

Adoption of IncuCyte® ZOOM enhances Sygnature Discovery’s Capabilities

16th March 2016 – Nottingham, UK – Sygnature Discovery Limited, a company which undertakes integrated drug discovery projects for pharmaceutical and biotechnology companies worldwide, from target validation to development candidate, today announced the addition of the IncuCyte® ZOOM real-time quantitative live-cell analysis technology into its Bioscience Department. In July 2015, Sygnature and Essen BioScience Ltd., […]

Sygnature Discovery and RenaSci Establish Strategic Alliance focused on Metabolic and CNS Disorders

15th February 2016 – Nottingham, UK – Sygnature Discovery Limited, a company which undertakes integrated drug discovery projects for pharmaceutical and biotechnology companies worldwide, from target validation to development candidate, and RenaSci Limited, a company providing an integrated blend of consultancy and experimental services to the global pharmaceutical industry to help maximise research productivity and […]

Sygnature Discovery delivers over 21K novel compounds to the European Lead Factory, one of the top performing SMEs in the consortium

Nottingham, UK – 3rd February 2016 Sygnature Discovery has announced that is has delivered in excess of 21,000 novel chemical compounds to the Public Compound Collection (PCC) of the European Lead Factory (ELF). The ELF, initiated in 2013, is a €196 million collaborative venture financed by the Innovative Medicines Initiative (IMI) and is aimed at […]

Sygnature Discovery starts 2016 with two key appointments as expansion continues.

Dr Stephen Young has been appointed as Vice-President, Business Development, joining from Chinese CRO start-up, Hitgen where he was VP of Business Development and responsible for establishing several early research collaborations. Prior to working at Hitgen, Stephen has held business development positions at Pharmacia, Novabiochem and Protherics. Stephen is a highly experienced Medicinal Chemist and […]

Page 10 of 15« First...89101112...Last »
Copyright © 2018 Sygnature Discovery

Website built by AtomicMedia - Design by Freestyle.